Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Combination therapy: the propitious rationale for drug development.

Phougat N, Khatri S, Singh A, Dangi M, Kumar M, Dabur R, Chhillar AK.

Comb Chem High Throughput Screen. 2014 Jan;17(1):53-67. Review.

PMID:
24138510
[PubMed - indexed for MEDLINE]
2.

Resistant gram-negative bacilli: A neglected healthcare crisis?

Lautenbach E, Polk RE.

Am J Health Syst Pharm. 2007 Dec 1;64(23 Suppl 14):S3-21; quiz S22-4.

PMID:
18029939
[PubMed - indexed for MEDLINE]
3.

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America.

Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17.

PMID:
23599308
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.

Lee SY, Kuti JL, Nicolau DP.

Surg Infect (Larchmt). 2005 Fall;6(3):283-95. Review.

PMID:
16201938
[PubMed - indexed for MEDLINE]
5.

New antibiotics for bad bugs: where are we?

Bassetti M, Merelli M, Temperoni C, Astilean A.

Ann Clin Microbiol Antimicrob. 2013 Aug 28;12:22. doi: 10.1186/1476-0711-12-22. Review.

PMID:
23984642
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Will new antimicrobials overcome resistance among Gram-negatives?

Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):909-22. doi: 10.1586/eri.11.107. Review.

PMID:
21973303
[PubMed - indexed for MEDLINE]
7.

Combination therapy as a tool to prevent emergence of bacterial resistance.

Mouton JW.

Infection. 1999;27 Suppl 2:S24-8. Review.

PMID:
10885823
[PubMed - indexed for MEDLINE]
8.

Antibiotic resistance: from Darwin to Lederberg to Keynes.

Amábile-Cuevas CF.

Microb Drug Resist. 2013 Apr;19(2):73-87. doi: 10.1089/mdr.2012.0115. Epub 2012 Oct 9.

PMID:
23046150
[PubMed - indexed for MEDLINE]
9.

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.

Cornaglia G, Rossolini GM.

Clin Microbiol Infect. 2009 Mar;15(3):218-23. doi: 10.1111/j.1469-0691.2009.02740.x. Review.

PMID:
19335369
[PubMed - indexed for MEDLINE]
10.

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J.

Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011. Review.

PMID:
19035777
[PubMed - indexed for MEDLINE]
Free Article
11.

Surveillance and management of multidrug-resistant microorganisms.

Orsi GB, Falcone M, Venditti M.

Expert Rev Anti Infect Ther. 2011 Aug;9(8):653-79. doi: 10.1586/eri.11.77. Review.

PMID:
21819331
[PubMed - indexed for MEDLINE]
12.

Pathogens resistant to antibacterial agents.

Chen LF, Chopra T, Kaye KS.

Infect Dis Clin North Am. 2009 Dec;23(4):817-45, vii. doi: 10.1016/j.idc.2009.06.002. Review.

PMID:
19909886
[PubMed - indexed for MEDLINE]
13.

Late stage antibacterial drugs in the clinical pipeline.

Projan SJ, Bradford PA.

Curr Opin Microbiol. 2007 Oct;10(5):441-6. Epub 2007 Oct 22. Review.

PMID:
17950658
[PubMed - indexed for MEDLINE]
14.

New antibiotic agents in the pipeline and how they can help overcome microbial resistance.

Gould IM, Bal AM.

Virulence. 2013 Feb 15;4(2):185-91. doi: 10.4161/viru.22507. Epub 2013 Jan 9. Review.

PMID:
23302792
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Combination approaches to combat multidrug-resistant bacteria.

Worthington RJ, Melander C.

Trends Biotechnol. 2013 Mar;31(3):177-84. doi: 10.1016/j.tibtech.2012.12.006. Epub 2013 Jan 18. Review.

PMID:
23333434
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients?

Hathorn JW, Pizzo PA.

J Antimicrob Chemother. 1986 Mar;17 Suppl A:41-54. Review.

PMID:
3519563
[PubMed - indexed for MEDLINE]
17.

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.

PMID:
23979759
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The use of new and better antibiotics for bacterial infections in patients with leukemia.

Rolston KV.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S357-63. doi: 10.3816/CLM.2009.s.035. Review.

PMID:
19778864
[PubMed - indexed for MEDLINE]
19.

[Calculated antibiotic therapy in gastroenterologic infections].

Braun RW.

Praxis (Bern 1994). 2003 Aug 13;92(33):1343-9. Review. German.

PMID:
14502790
[PubMed - indexed for MEDLINE]
20.

Antibiotic resistance--experience in a tertiary care hospital in south India.

Subbalaxmi MV, Lakshmi V, Lavanya V.

J Assoc Physicians India. 2010 Dec;58 Suppl:18-22. No abstract available.

PMID:
21568007
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk